Diagnosis and staging of pancreatic ductal adenocarcinoma

• C. Guillén-Ponce ^[1] ; J. Blázquez ^[1] ; I. González ^[3] ; E. de-Madaria ^[2] ; J. Montáns ^[4] ; A. Carrato ^[1]
  1. [1] Hospital Ramón y Cajal

     Hospital Ramón y Cajal

     Madrid, España

     
  2. [2] Hospital General Universitario de Alicante

     Hospital General Universitario de Alicante

     Alicante, España

     
  3. [3] Complejo Hospitalario de Granada, España
  4. [4] Centro Anatomopatológico, Madrid, España

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 19, Nº. 10 (October 2017), 2017, págs. 1205-1216
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • The management of pancreatic ductal adenocarcinoma (PDAC) is a major public health concern worldwide. Currently, most PDAC patients are diagnosed in advanced stages. The signs and symptoms of the disease, except for jaundice, are non-specific. Thus, the current challenge is to identify earlier those individuals for whom specific screening tools and specific treatments would be beneficial. On the basis of the recommendations of the group of experts of multiple medical specialties of the GALLgo Project, the patients with PDAC should be managed by a multidisciplinary team to assess the personal and family history, the best diagnostic and staging procedures and consider all important aspects for treatment decisions. In this article, the group of experts proposes strategies to shorten the diagnosis times in PDAC patients.